

Intranasal delivery system as new treatment paradigm for the treatment of postmenopausal osteoporosis

Dr. Foziyah Zakir

Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India

Abstract:

Osteoporosis is the most prevailing disease in postmenopausal women leading to increased risk of fractures, pain and low quality of life. It is a progressive bone disease which remains unnoticed until a fracture occurs. The disease is more predominant in older age population particularly females due to reduced estrogen levels and limited calcium absorption. The cost burden of treating osteoporotic fractures is too expensive therefore primary focus should be treatment at an early stage. Most of the marketed drugs are available as oral delivery dosage forms. The complications as well as patient non-compliance limit the use of oral therapy for prolonged drug delivery. Intranasal delivery system seems to be a promising approach for systemic delivery of drugs through nasal cavity bypassing the first-pass effect. Intranasal delivery has the potential to improve the absorption of the drug, enhance the bioavailability, and provide better patient compliance as well as possibility of self administration. Most of the osteoporotic medications are not absorbed orally due to proteomic nature or first pass metabolism. Therefore, a suitable delivery system can be designed to promote intranasal delivery of therapeutics. We have developed an intranasal in-situ thermosensitive nanoemulgel of raloxifene hydrochloride to overcome the pharmaco-technical limitations of the drug. The delivery system boosted the bioavailability of raloxifene hydrochloride by 7 fold and improved the bone mineral density by 162% when compared with marketed oral tablets.

Biography:

Dr. Zakir has completed her PhD from Jamia Hamdard (NIRF rank 1), India. Dr. Zakir is currently working as an Asst. Prof., Delhi Pharmaceutical Sciences and Research University (India's First Pharmacy University and second in the world). She has more than 20 referred articles in high impact journals >4 (h-index=9, >400 citations). She has authored numerous book chapters by Elsevier and Bentham publishers. She has published more than 50 conference proceedings and abstracts. Dr. Zakir has received research funding of 20,00,00 INR from Department of Science and Technology. She has received Award for Academic Excellence in 2010.

Note: This work is partly presented at Webinar on Pharmaceutics and drug discovery (London UK, February 27)